Sign inTwo ways to find something worth building: what people are reporting as problems, and what this country is paying foreigners for. Both are ranked; neither is combined into the other.
Country · 2019–2024 · 60,550 trade records
One dot is one manufactured product this country imports. Hover to see which; click for the pathway and what it might cost to start. Both axes are annual trade, on a log scale — each gridline is ten times the last — because the figures span three and a half orders of magnitude and a linear axis would stack all but the largest onto the origin. Computed Nov 10, 2026 · 00:00 UTC.
20 of 49 sit below the parity line — the country buys more of that product than it sells. That gap is the opportunity; the ones above it are already served by domestic makers. These are the top 49 manufactured products out of 49 scored.
| Product | HS code | Annual imports | Annual exports | Buys per unit sold |
|---|---|---|---|---|
| Medicaments; consisting of mixed or unmixed products n.e.c. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | 300490 | $894.6M | $17.6B | 0.0x |
| Vaccines; for human medicine | 300220 | $443.9M | $1.1B | 0.4x |
| Vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products; for human medicine | 300241 | $344.6M | $1B | 0.3x |
| Blood, human or animal, antisera, other blood fractions and immunological products; immunological products, put up in measured doses or in forms or packings for retail sale | 300215 | $460.3M | $282.2M | 1.6x |
| Medicaments; containing antibiotics (other than penicillins, streptomycins or their derivatives), for therapeutic or prophylactic uses, packaged for retail sale | 300420 | $52.2M | $1.1B | 0.0x |
| Medicaments; containing insulin, for therapeutic or prophylactic uses, packaged for retail sale | 300431 | $188.4M | $146.3M | 1.2x |
| Blood, human or animal, antisera, other blood fractions and immunological products; antisera and other blood fractions | 300212 | $201.8M | $127.2M | 1.5x |
| Medicaments; (not containing antibiotics, hormones, alkaloids or their derivatives), for therapeutic or prophylactic uses, (not packaged for retail sale) | 300390 | $57.9M | $304.5M | 0.1x |
| Medicaments; containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | 300439 | $53M | $213M | 0.2x |
| Glands and other organs; heparin and its salts; other human or animal substances prepared for therapeutic or prophylactic uses, n.e.c. in heading 3001 | 300190 | $55.3M | $61.1M | 0.9x |
| Pharmaceutical goods; opacifying preparations for x-ray examinations, diagnostic reagents designed to be administered to the patient | 300630 | $80.7M | $38.3M | 2.1x |
| Pharmaceutical goods; dental cements and other dental fillings, bone reconstruction cements | 300640 | $43.9M | $16.1M | 2.7x |
| Toxins, cultures of micro-organisms (excluding yeasts) and similar products | 300290 | $38.5M | $32.7M | 1.1x |
| Vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products; for veterinary medicine | 300242 | $67.3M | $13.3M | 5.0x |
| Toxins, cultures of micro-organisms (excluding yeasts) and similar products; n.e.c. in item 3002.3 | 300249 | $65.4M | $42.2M | 1.5x |
| Wadding, gauze, bandages and similar articles; (excluding adhesive dressings), impregnated or coated with pharmaceutical substances, packaged for retail sale | 300590 | $21.4M | $83.6M | 0.2x |
| Pharmaceutical goods; chemical contraceptive preparations based on hormones, on other products of heading 2937 or on spermicides | 300660 | $10.6M | $163.5M | 0.0x |
| Medicaments; containing vitamins or their derivatives, for therapeutic or prophylactic use, packaged for retail sale | 300450 | $2.2M | $294.7M | 0.0x |
| Medicaments; containing penicillins, streptomycins or their derivatives, for therapeutic or prophylactic uses, packaged for retail sale | 300410 | $3.6M | $745.8M | 0.0x |
| Vaccines; for veterinary medicine | 300230 | $44.9M | $9.9M | 4.5x |
| Medicaments; containing hormones (excluding insulin), (but not containing antibiotics), for therapeutic or prophylactic uses, not packaged for retail sale | 300339 | $34.6M | $2.3M | 14.5x |
| Blood, human or animal, antisera, other blood fractions and immunological products; n.e.c. in heading 3002.1 | 300219 | $63.4M | $5.4M | 11.6x |
| Pharmaceutical goods; sterile surgical catgut, suture materials, tissue adhesives, laminaria, laminaria tents, absorbable surgical or dental haemostatics, and surgical or dental adhesion barriers | 300610 | $15.2M | $48.9M | 0.3x |
| Medicaments; containing alkaloids or their derivatives; other than ephedrine, pseudoephedrine (INN) or norephedrine or their salts; for therapeutic or prophylactic uses, packaged for retail sale | 300449 | $10.2M | $27.8M | 0.3x |
| Dressings, adhesive; and other articles having an adhesive layer, packed for retail sale for medical, surgical, dental or veterinary purposes | 300510 | $22.1M | $12.2M | 1.8x |
| Medicaments; containing corticosteroid hormones, their derivatives or structural analogues (but not containing antibiotics), for therapeutic or prophylactic uses, packaged for retail sale | 300432 | $6.9M | $164.2M | 0.0x |
| Pharmaceutical goods; appliances identifiable for ostomy use | 300691 | $14.7M | $2.9M | 4.9x |
| Medicaments; containing antibiotics other than penicillins, streptomycins and their derivatives, for therapeutic or prophylactic uses, (not in measured doses, not packaged for retail sale) | 300320 | $16.9M | $5.7M | 2.9x |
| Blood, human or animal, antisera, other blood fractions and immunological products; malaria diagnostic test kits | 300211 | $2.4M | $36.6M | 0.0x |
| Blood, human or animal, antisera, other blood fractions and immunological products; immunological products, mixed, put up in measured doses or in forms or packings for retail sale | 300214 | $2.9M | $23.3M | 0.1x |
| Medicaments; containing antimalarial active principles described in Subheading Note 2 to this Chapter, for therapeutic or prophylactic uses, packaged for retail sale | 300460 | $44 | $196.4M | 0.0x |
| Pharmaceutical goods; placebos and blinded (or double-blinded) clinical trial kits for a recognised clinical trial, put up in measured doses | 300693 | $10.4M | $355.9K | 29.4x |
| Pharmaceutical goods; Gel preparations designed to be used in human or veterinary medicine as a lubricant for parts of the body for surgical operations or physical examinations or as a coupling agent between the body and medical instruments | 300670 | $3.6M | $6.5M | 0.5x |
| Blood, human or animal, antisera, other blood fractions and immunological products; immunological products, unmixed, not put up in measured doses or in forms or packings for retail sale | 300213 | $7.2M | $6.1M | 1.1x |
| Pharmaceutical goods; blood-grouping reagents | 300620 | $8.4M | $443.4K | 19.0x |
| Cell cultures, whether or not modified; other cell cultures not including cell therapy products | 300259 | $2.6M | $197K | 13.4x |
| Glands and other organs; extracts of glands or other organs or of their secretions, for organo-therapeutic uses | 300120 | $6.4M | $361.8K | 17.9x |
| Medicaments; containing alkaloids or their derivatives, containing ephedrine or its salts, for therapeutic or prophylactic uses, (not packaged for retail sale) | 300341 | $1.1K | $2.3M | 0.0x |
| Medicaments; containing alkaloids or their derivatives; other than ephedrine, pseudoephedrine (INN) or norephedrine or their salts; for therapeutic or prophylactic uses, (not packaged for retail sale) | 300349 | $20.2K | $1.5M | 0.0x |
| Medicaments; containing penicillins, streptomycins or their derivatives, for therapeutic or prophylactic uses, (not in measured doses, not packaged for retail sale) | 300310 | $26.8K | $3.3M | 0.0x |
| Pharmaceutical goods; first aid boxes and kits | 300650 | $331.5K | $891.1K | 0.3x |
| Medicaments; containing antimalarial active principles described in subheading note 2 to this chapter, for therapeutic or prophylactic uses, (not packaged for retail sale) | 300360 | $16 | $386.2K | 0.0x |
| Medicaments; containing alkaloids or their derivatives, containing ephedrine or its salts, for therapeutic or prophylactic uses, packaged for retail sale | 300441 | $107 | $662.9K | 0.0x |
| Pharmaceutical goods; waste pharmaceuticals | 300692 | $77 | $15K | 0.0x |
| Medicaments; containing alkaloids or their derivatives, containing pseudoephedrine (INN) or its salts, for therapeutic or prophylactic uses, packaged for retail sale | 300442 | $65 | $28.9K | 0.0x |
| Cell cultures, whether or not modified; cell therapy products | 300251 | $1.7K | $61.8K | 0.0x |
| Medicaments; containing alkaloids or their derivatives, containing norephedrine or its salts, for therapeutic or prophylactic uses, (not packaged for retail sale) | 300343 | $122 | $118 | 1.0x |
| Medicaments; containing insulin, for therapeutic or prophylactic uses, not packaged for retail sale | 300331 | $10 | $970 | 0.0x |
| Medicaments; containing alkaloids or their derivatives, containing norephedrine or its salts, for therapeutic or prophylactic uses, packaged for retail sale | 300443 | $29 | $20.3K | 0.0x |
Pick a dot to see what that product would take to make here.
Categories where people are reporting problems and the country imports heavily. A coincidence worth looking at — not a combined score. The two numbers count different things and are shown separately for that reason.
No category currently clears the bar on both sides. That is a real finding: it means the problems people are reporting and the goods the country buys abroad are not pointing at the same place yet.
Joined on the research category, which is the coarsest link available — eight categories cover every commodity. Treat it as a hint about where to look, not as a match between a reported problem and a product.
A ranking is only as honest as its exclusions.